Barclays’s Cymabay Therapeutics CBAY Stock Holding History

Barclays’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30,000	Closed	-$709K	–	5448
2023 Q4	$709K	Buy	+30,000	New	+$534K	﹤0.01%	3671

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's CBAY Position: Q1 2024 in Review

Barclays sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 190,332 shares — an estimated $4.5M sold.

Barclays first reported a position in CBAY in Q3 2014 and held it in 30 quarters. The position peaked at $4.5M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Barclays reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Barclays sold 190,332 Cymabay Therapeutics shares in Q1 2024, an estimated $4.5M.
Barclays first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 30 quarters.
Barclays's Cymabay Therapeutics position peaked at $4.5M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.